etoposide has been researched along with tamoxifen in 85 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (7.06) | 18.7374 |
| 1990's | 18 (21.18) | 18.2507 |
| 2000's | 31 (36.47) | 29.6817 |
| 2010's | 28 (32.94) | 24.3611 |
| 2020's | 2 (2.35) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Cai, W; Hao, Y; Hu, P; Ma, D; Pan, H; Xie, X; Yu, AD; Yu, J; Yuan, J; Zhang, L; Zhu, H | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Cho, H; Elkamhawy, A; Heo, JC; Kim, HY; Kim, KH; Lee, CO; Nam, DH; Pae, AN; Park, WK; Roh, EJ; Seol, HJ; Viswanath, AN; Yang, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Chanda, D; Dudi, RK; Fatima, K; Iqbal, H; Khan, F; Kumar, Y; Luqman, S; Mondhe, DM; Negi, AS; Shanker, K; Tabassum, M; Verma, AK | 1 |
| Brunner, KW; Cavalli, F | 1 |
| Cavalli, F | 1 |
| Carmichael, J; Harris, AL; Houlbrook, S; Kirk, J; Lien, EA; Philip, P; Stuart, NS; Tonkin, K | 1 |
| Cantwell, BM; Carmichael, J; Harris, AL; Lien, EA; Millward, MJ | 1 |
| Arnold, A; Figueredo, A; Findlay, B; Goodyear, M; Jones, A; Neville, A; Normandeau, R | 1 |
| Jacobs, P; Martell, RW; Wilson, EL | 1 |
| Lutz, D | 1 |
| Achterrath, W; Balleisen, L; Büchner, T; Hiddemann, W; Preusser, P; Urbanitz, D | 1 |
| Schwarz, MA; Snyder, RD | 1 |
| Pawlicki, M; Zuchowska-Vogelgesang, B | 1 |
| Carpentier, AF; Chantelard, JV; Henin, D; Poisson, M | 1 |
| Smith, DC; Trump, DL | 1 |
| Cheson, BD; Feigal, EG; Phillips, PH | 1 |
| Ciavattini, A; Cignitti, M; De Nictolis, M; Garzetti, GG; Goteri, G; Romanini, C; Tranquilli, AL | 1 |
| Chen, BR; Chen, DS; Chen, YC; Cheng, AL; Chuang, SE; Yeh, KH | 1 |
| Bender, JG; Blake, M; Carreon, J; Lee, WJ; Oldham, F; Schilling, M; Smith, S; Swinney, P; Van Epps, D; Williams, DE; Williams, SF; Zimmerman, T | 1 |
| Anteby, SO; Edelman, DZ; Peretz, T | 1 |
| Arvizu, C; Conzen, SD; Kaufman, PA; LeMarbre, P; Maurer, LH; Mills, LE; Mott, LA | 1 |
| Aebi, S; Fink, D; Haas, M; Howell, SB; Kim, HK; Nebel, S; Norris, PS | 1 |
| Burgio, DE; Gosland, MP | 1 |
| Cheng, AL; Lin, JF; Yang, CH; Yang, PC; Yeh, KH; Yu, CJ | 1 |
| Bernard, EA; da Rocha, AB; Leyva, A; Logullo, AF; Mans, DR; Ruschel, C; Schwartsmann, G; Wetmore, LA | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Sartor, F; Sorio, R; Toffoli, G | 1 |
| Bashey, A; Corringham, RE; Corringham, S; Garrett, J; Gilpin, EA; Ho, AD; Lane, TA; Law, P | 1 |
| Ames, F; Asmar, L; Booser, DJ; Brito, RA; Buzdar, AU; Frye, D; Hortobagyi, GN; Kau, SW; McNeese, M; Ross, M; Singletary, SE; Strom, E; Theriault, RL; Valero, V | 1 |
| Fenton, LZ; Foreman, NK; Madden, JR; Partington, M; Weil, M; Winston, KR | 1 |
| Lichtman, SM; Skirvin, JA | 1 |
| Hensley, ML | 1 |
| Kylmä, J; Nazhat, SN; Rich, J; Seppälä, J; Tanner, KE; Tuominen, J | 1 |
| Kim, R; Kocarek, TA; Lan, L; Schuetz, E; Schuetz, J; Strom, S; Yasuda, K | 1 |
| Obrero, M; Shapiro, DJ; Yu, DV | 1 |
| Clark, AS; Dennis, PA; Streicher, S; West, K | 1 |
| Aydingöz, U; Ayhan, A; Erman, M; Güler, N; Karaoğlu, A; Oksüzoğlu, B | 1 |
| McEleney, K; Welsh, J; Zinser, GM | 1 |
| Anderson, JS; Daniel, KG; Dou, QP; Gupta, P; Kazi, A; Zhong, Q | 1 |
| Chin, K; Furuta, N; Hatake, K; Itoh, Y; Mishima, Y; Mizunuma, N; Nagasaki, E; Shinozaki, E; Takahashi, S; Terui, Y; Tokutome, N; Usui, N | 1 |
| Ekinci, C; Günalp, I; Gündüz, K; Taçyildiz, N; Unal, E; Yavuz, G | 1 |
| Diedrich, K; Ortmann, O; Treeck, O; Zhou, R | 1 |
| Bogart, J; Evans, L; Green, MR; Herndon, JE; McClay, EF; Seagren, SL; Watson, D | 1 |
| Amador, R; Aparicio, J; Beltrán, A; Calderero, V; Díaz, R; Jordá, MV; Reynés, G; Segura, A | 1 |
| Chin, WW; Dantzig, AH; Iversen, PW; Jin, S; Krishnan, V; Lesoon, A; Moore, RE; O'Brien, KA; Peek, VL; Perry, WL; Rolfe, M; Sampath, J; Shepard, RL; Shyjan, A; Tighe, M; Williamson, M; Yaden, B | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
| Cheng, J; Shapiro, DJ; Yu, DV; Zhou, JH | 1 |
| Ghafourifar, P; Parihar, A; Parihar, MS | 1 |
| Guo, T; Härkönen, P; Kallio, A; Kangas, L; Lamminen, E; Seppänen, J; Väänänen, HK | 1 |
| Han, X; Lv, J; Shi, J; Sun, Y; Wang, S; Xia, W; Xu, S; Zhao, T | 1 |
| Arima, N; Hayashi, M; Nishimura, R; Okumura, Y; Osako, T | 1 |
| Cai, JY; Chen, J; Dong, L; Jiang, H; Pan, C; Shen, SH; Tang, JY; Xu, M; Xue, HL; Ye, QD; Zhou, M | 1 |
| Abrams, SL; Chappell, WH; Drobot, LB; Franklin, RA; Libra, M; Martelli, AM; McCubrey, JA; Nicoletti, F; Sokolosky, ML; Stadelman, KM; Steelman, LS; Stivala, F | 1 |
| Blagden, S; Gabra, H; Graham, J; Sharma, R | 1 |
| Farkas, T; Frankel, LB; Høyer-Hansen, M; Jäättelä, M; Krogh, A; Lees, M; Lund, AH; Wen, J | 1 |
| Balashova, EE; Dashtiev, MI; Lokhov, PG | 1 |
| Karantzelis, N; Kotsantis, P; Lygerou, Z; Nishitani, H; Petropoulou, C; Roukos, V; Stathopoulou, A; Taraviras, S | 1 |
| Banin, VV; Borisova, LM; Fedotcheva, TA; Kiseleva, MP; Rzheznikov, VM; Semeĭkin, AV; Shimanovskiĭ, NL; Shirokikh, KE; Smirnova, zS; Tolkachev, VN | 1 |
| Chow, CL; Gubbels, SP; Guo, W; Trivedi, P; Zhao, X | 1 |
| Blanchard, A; Han, J; Leygue, E; Ma, X; Myal, Y; Schroedter, I; Wang, N; Zhou, B | 1 |
| Boyd, JD; Brightsmith, DJ; Hoppes, SM | 1 |
| Kuo, YC; Wang, IH | 1 |
| Antona, AD; Cipolla, C; Ciulla, A; Graceffa, G; Grillo, A; Locurto, P; Martorana, S; Vieni, S | 1 |
| Banavali, S; Devadas, SK | 1 |
| Alves, A; Gouveia, TIA; Mota, IH; Santos, MSF; Silva, AMT | 1 |
9 review(s) available for etoposide and tamoxifen
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
[New substances in oncologic therapy].
Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Evaluation, Preclinical; Etoposide; Humans; Neoplasms; Nitrosourea Compounds; Razoxane; Tamoxifen; Vinca Alkaloids; Zinostatin | 1978 |
[New antineoplastic agents, their value and use].
Topics: Aminacrine; Antineoplastic Agents; Aspartic Acid; Cisplatin; Etoposide; Humans; Ifosfamide; Interferons; Medroxyprogesterone; Medroxyprogesterone Acetate; Methyltestosterone; Neoplasms; Phosphonoacetic Acid; Razoxane; Tamoxifen; Teniposide; Vinca Alkaloids | 1982 |
[Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Ovarian Neoplasms; Paclitaxel; Recurrence; Tamoxifen | 1996 |
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Complementary Therapies; Cytochrome P-450 Enzyme System; Dacarbazine; Etoposide; Humans; Idarubicin; Neoplasms; Tamoxifen; Temozolomide; Thalidomide; Topotecan | 2002 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
Primary neuroendocrine carcinoma of the breast A single Center experience and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Estrogens; Etoposide; Female; Humans; Mastectomy; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Progesterone; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Receptors, Steroid; Retrospective Studies; Sentinel Lymph Node Biopsy; Tamoxifen | 2016 |
17 trial(s) available for etoposide and tamoxifen
| Article | Year |
|---|---|
[New substances in oncologic therapy].
Topics: Altretamine; Ancitabine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Mitolactol; Nitrosourea Compounds; Razoxane; Remission, Spontaneous; Tamoxifen; Time Factors; Vinca Alkaloids; Zinostatin | 1978 |
High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Humans; Male; Membrane Glycoproteins; Middle Aged; Neoplasms; Tamoxifen; Tumor Cells, Cultured; Verapamil | 1992 |
Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cricetinae; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Synergism; Etoposide; Female; Humans; Male; Neoplasms; Tamoxifen | 1992 |
Chemotherapy of adult acute nonlymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitolactol; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Tamoxifen | 1990 |
A phase I trial of high-dose oral tamoxifen and CHOPE.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Prednisone; Tamoxifen; Vincristine | 1995 |
Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Schedule; Etoposide; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Tamoxifen | 1996 |
Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Culture Techniques; Cells, Cultured; Combined Modality Therapy; Culture Media; Cyclophosphamide; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunomagnetic Separation; Leukapheresis; Lewis X Antigen; Melphalan; Middle Aged; Neutropenia; Tamoxifen; Thiotepa; Thrombocytopenia | 1996 |
Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Etoposide; Female; Humans; Middle Aged; Mitoxantrone; Tamoxifen | 1996 |
High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Tamoxifen | 1999 |
Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Hepatocellular; Drug Interactions; Etoposide; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Binding; Tamoxifen; Time Factors | 1999 |
A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Liver Neoplasms; Middle Aged; Mitoxantrone; Platelet Count; Soft Tissue Neoplasms; Survival Rate; Tamoxifen; Thiotepa; Transplantation, Autologous | 2000 |
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prednisone; Prospective Studies; Radiography; Survival Analysis; Tamoxifen; Treatment Outcome; Vincristine | 2001 |
A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Survival Analysis; Tamoxifen | 2005 |
Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: a single-center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cisplatin; Drug Administration Schedule; Etoposide; Female; Glioblastoma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Survival Rate; Tamoxifen | 2005 |
Results of RS-99 protocol for childhood solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Neoplasms, Germ Cell and Embryonal; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prognosis; Radiotherapy, Adjuvant; Rhabdomyosarcoma; Sarcoma, Ewing; Tamoxifen; Vincristine | 2010 |
Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Carboplatin; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Granulosa Cell Tumor; Humans; Middle Aged; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Peripheral Nervous System Diseases; Salvage Therapy; Tamoxifen; Thrombocytopenia; Treatment Outcome | 2011 |
Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
Topics: Administration, Metronomic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rhabdomyosarcoma; Salvage Therapy; Sarcoma; Sarcoma, Ewing; Survival Rate; Tamoxifen; Young Adult | 2019 |
59 other study(ies) available for etoposide and tamoxifen
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
Topics: Autophagy; Calcium Channel Blockers; Cell Line, Tumor; Drug Evaluation, Preclinical; Fluspirilene; Glioblastoma; Green Fluorescent Proteins; Humans; Intracellular Membranes; Loperamide; Microtubule-Associated Proteins; Mycotoxins; Peptides; Phagosomes; Phosphatidylinositol Phosphates; Pimozide; Protein Kinases; Recombinant Fusion Proteins; Sirolimus; Small Molecule Libraries; TOR Serine-Threonine Kinases; Trifluoperazine; Zinc Fingers | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Molecular; Molecular Conformation; Quinazolines; Structure-Activity Relationship; Temozolomide; Urea | 2015 |
Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; G2 Phase Cell Cycle Checkpoints; Humans; Male; Mice; Molecular Docking Simulation; Naphthalenes; Pyrrolidines; Topoisomerase II Inhibitors; Tubulin Modulators | 2020 |
Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Tamoxifen; Time Factors; Verapamil; Vincristine | 1990 |
[Various induction therapies in older patients with acute myeloid leukemias].
Topics: Aclarubicin; Adolescent; Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Danazol; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Tamoxifen | 1985 |
[AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia].
Topics: Aminoacridines; Aminoglutethimide; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Danazol; Drug Evaluation; Drug Resistance; Etoposide; Humans; Leukemia, Myeloid, Acute; Tamoxifen | 1985 |
Clinical trials in cancer medicine.
Topics: Adult; Antineoplastic Agents; Bleomycin; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Etoposide; Female; Humans; Male; Methotrexate; Platinum; Tamoxifen; Teniposide; Testicular Neoplasms | 1980 |
Osteosarcoma following radiation treatment for meningioma: report of a case and effective treatment with chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cisplatin; Dactinomycin; Etoposide; Female; Gonadotropin-Releasing Hormone; Humans; Ifosfamide; Lung Neoplasms; Meningeal Neoplasms; Meningioma; Methotrexate; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Osteosarcoma; Tamoxifen; Tomography, X-Ray Computed; Vincristine | 1994 |
Clinical trials referral resource. Small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Tamoxifen | 1993 |
Endometrioid carcinoma of the ovary. Retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Endometriosis; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Medroxyprogesterone; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Retrospective Studies; Survival Rate; Tamoxifen | 1993 |
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Cell Separation; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; DNA Repair; DNA, Neoplasm; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Melphalan; Paclitaxel; Tamoxifen; Thioguanine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1998 |
Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distribution.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Cyclosporine; Etoposide; Frontal Lobe; Male; Rats; Rats, Sprague-Dawley; Sodium Cyanide; Tamoxifen; Trifluoperazine | 1998 |
Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU.
Topics: Antineoplastic Agents; Carmustine; Cell Division; Drug Synergism; Etoposide; Gamma Rays; Glioblastoma; Humans; Immunohistochemistry; Protein Kinase C; Receptors, Estrogen; Tamoxifen; Transforming Growth Factor beta; Tumor Cells, Cultured | 1999 |
Experience with tamoxifen/etoposide in the treatment of a child with myxopapillary ependymoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ependymoma; Estrogen Receptor Modulators; Etoposide; Female; Humans; Laminectomy; Low Back Pain; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Spinal Cord Neoplasms; Tamoxifen; Treatment Outcome | 2001 |
Lactic acid based PEU/HA and PEU/BCP composites: Dynamic mechanical characterization of hydrolysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Substitutes; Cisplatin; Composite Resins; Etoposide; Gamma Rays; Hydrolysis; Lactic Acid; Materials Testing; Mechanics; Mitoxantrone; Polyesters; Polyurethanes; Sodium Chloride; Sterilization; Tamoxifen | 2002 |
Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Etoposide; Genes, Reporter; Humans; Male; Mice; Mice, Inbred C57BL; Mixed Function Oxygenases; Pregnane X Receptor; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Tamoxifen; Topotecan; Transcription, Genetic | 2002 |
Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Cell Fractionation; Cell Size; Estradiol; Estrogen Antagonists; Etoposide; Fulvestrant; Genes, Reporter; HeLa Cells; Humans; Microscopy, Electron; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteins; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Transcriptional Activation | 2002 |
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Chromones; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Etoposide; Flow Cytometry; Humans; Immunoblotting; Morpholines; Paclitaxel; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Tamoxifen; Time Factors; Transfection; Trastuzumab; Tumor Cells, Cultured | 2002 |
Solitary esophageal metastasis of breast cancer after 11 years: a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Deglutition Disorders; Diagnosis, Differential; Doxorubicin; Esophageal Neoplasms; Etoposide; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Radiography; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2002 |
Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
Topics: Alitretinoin; Animals; Apoptosis; Calcitriol; Cell Line, Tumor; Estrogens; Ethanol; Etoposide; Female; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Mice, Nude; Pregnancy; Receptors, Calcitriol; Tamoxifen; Tretinoin | 2003 |
Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Autolysis; Breast Neoplasms; Calpain; Cytochrome c Group; Enzyme Activation; Enzyme Inhibitors; Etoposide; Female; Humans; Imidazoles; Jurkat Cells; Male; Mitochondria; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Protein Subunits; Tamoxifen; Tumor Cells, Cultured | 2003 |
[Simultaneous detection of both non-Hodgkin's lymphoma cells and breast cancer cells in pleural effusion--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Combinations; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pleural Effusion; Prednisone; Tamoxifen; Tegafur; Uracil; Vincristine | 2003 |
Encouraging result of tamoxifen in a retinoblastoma patient with central nervous system metastasis.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Eye Enucleation; Eye Neoplasms; Female; Glucocorticoids; Humans; Meningeal Neoplasms; Methotrexate; Retinoblastoma; Skull Neoplasms; Tamoxifen; Vincristine | 2003 |
Tamoxifen long-term treatment in vitro alters the apoptotic response of MCF-7 breast cancer cells.
Topics: Annexin A5; Apoptosis; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; Etoposide; Germany; Histones; Humans; Hybridization, Genetic; Oligonucleotide Array Sequence Analysis; Receptor, ErbB-2; RNA; Staining and Labeling; Tamoxifen; Time Factors; Tumor Cells, Cultured; Up-Regulation | 2004 |
Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.
Topics: Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Estrogen Receptor beta; Etoposide; Female; Humans; Mitoxantrone; Ovarian Neoplasms; Pyrrolidines; RNA Splicing; RNA Splicing Factors; RNA-Binding Proteins; RNA, Catalytic; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Transfection | 2005 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
Tamoxifen induction of CCAAT enhancer-binding protein alpha is required for tamoxifen-induced apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; CCAAT-Enhancer-Binding Protein-alpha; Estrogen Antagonists; Estrogen Receptor alpha; Etoposide; Gene Expression Profiling; Gene Expression Regulation; HeLa Cells; Humans; Mutation; Oligonucleotide Array Sequence Analysis; RNA, Small Interfering; Tamoxifen | 2007 |
Significance of mitochondrial calcium and nitric oxide for apoptosis of human breast cancer cells induced by tamoxifen and etoposide.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Calcium; Cell Line, Tumor; Cytochromes c; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Membrane Potential, Mitochondrial; Mitochondria; Nitric Oxide; Tamoxifen; Time Factors; Tyrosine | 2008 |
Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Etoposide; Humans; Interleukin-6; Osteoblasts; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Female; Glycoproteins; Humans; Pyrazoles; Sulfonamides; Tamoxifen | 2009 |
Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cell Proliferation; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Ki-67 Antigen; Logistic Models; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Tamoxifen; Taxoids; Tumor Suppressor Protein p53 | 2010 |
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Molecular Targeted Therapy; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases | 2011 |
microRNA-101 is a potent inhibitor of autophagy.
Topics: Autophagy; Autophagy-Related Proteins; Breast Neoplasms; Cell Line, Tumor; Cysteine Endopeptidases; Etoposide; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; rab5 GTP-Binding Proteins; RNA Interference; RNA, Small Interfering; Sirolimus; Stathmin; Tamoxifen | 2011 |
Proteomic footprinting of drug-treated cancer cells as a measure of cellular vaccine efficacy for the prevention of cancer recurrence.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cancer Vaccines; Chromatography, Liquid; Dendritic Cells; Doxorubicin; Etoposide; Female; Hep G2 Cells; Humans; Neoplasm Recurrence, Local; Proteomics; Receptors, Cell Surface; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; T-Lymphocytes, Cytotoxic; Tamoxifen; Tumor Cells, Cultured | 2012 |
Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; HeLa Cells; Hep G2 Cells; Humans; Methyl Methanesulfonate; Neoplasms; Proteolysis; Tamoxifen; Ultraviolet Rays | 2012 |
[Antitumor and antiproliferative action of the steroidal cytostatic antiestrogen cytestrol acetate on hormone-dependent tumor models].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cytostatic Agents; Doxorubicin; Drug Administration Schedule; Drug Synergism; Estrogen Antagonists; Ethinyl Estradiol; Etoposide; Female; Humans; Inhibitory Concentration 50; Injections, Subcutaneous; Mice; Rats; Tamoxifen; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Characterization of a unique cell population marked by transgene expression in the adult cochlea of nestin-CreER(T2)/tdTomato-reporter mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cochlea; Ear, Inner; Estrogen Antagonists; Etoposide; Female; Gene Expression Regulation; Ifosfamide; Ki-67 Antigen; Luminescent Proteins; Male; Membrane Proteins; Methotrexate; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nerve Tissue Proteins; Nestin; Neurons; Plant Lectins; Receptors, Estrogen; Tamoxifen | 2015 |
Claudin 1 promotes migration and increases sensitivity to tamoxifen and anticancer drugs in luminal-like human breast cancer cells MCF7.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cisplatin; Claudin-1; Down-Regulation; Etoposide; Female; Gene Expression; Humans; MCF-7 Cells; Tamoxifen; Tight Junctions; Transforming Growth Factor beta | 2015 |
Impact of Delayed Analysis in Avian Blood Biochemical Values Measured With the Abaxis VetScan VS2.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; Blood Specimen Collection; Cisplatin; Etoposide; Mitoxantrone; Point-of-Care Systems; Psittaciformes; Tamoxifen; Time Factors | 2015 |
Enhanced delivery of etoposide across the blood-brain barrier to restrain brain tumor growth using melanotransferrin antibody- and tamoxifen-conjugated solid lipid nanoparticles.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Etoposide; Glioblastoma; Humans; Membrane Glycoproteins; Nanoparticles; Permeability; Tamoxifen | 2016 |
Are cytostatic drugs in surface waters a potential threat?
Topics: Child; Chlorambucil; Cyclophosphamide; Cyproterone; Cytostatic Agents; Drinking Water; Environmental Monitoring; Etoposide; Flutamide; Humans; Mycophenolic Acid; Pharmaceutical Preparations; Rivers; Tamoxifen; Water Pollutants, Chemical | 2022 |